Corvus Pharmaceuticals' Short Runway Overshadows Soquelitinib's Promising Trials
Corvus Pharmaceuticals suffered lately, especially after it announced in December 2024 its early AD data. Check out why I ...
Q4 2024 Corvus Pharmaceuticals Inc Earnings Call
Thank you for standing by and welcome to the Corvus Pharmaceuticals fourth-quarter and full-year 2024 business update and financial results conference call. (Operator Instructions) It is now my ...
Corvus Pharmaceuticals outlines clinical milestones for soquelitinib in 2025
Discover Corvus Pharmaceuticals' Q4 2024 earnings insights, highlighting soquelitinib's trial progress, upcoming milestones for 2025, and robust ...
Business Insider7d
Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results
Soquelitinib Atopic Dermatitis Phase 1 Clinical Trial Data From Cohorts 1-3 anticipated to be Presented in May Initial Results From First Two Cohorts Supports Safety and Efficacy with Oral Agent and ...
Business Insider13d
Corvus Pharmaceuticals Announces Presentation of Additional Data from the Phase 1/1b Clinical Trial of Soquelitinib for Patients with T Cell Lymphoma
March 20, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that additional data from the Company’s Phase 1/1b clinical ...
Nasdaq20d
Corvus Pharmaceuticals' Soquelitinib Enters Phase 2 Trial For ALPS
(RTTNews) - Corvus Pharmaceuticals (CRVS) announced that the National Institute of Allergy and Infectious Diseases or NIAID has initiated a Phase 2 clinical trial for soquelitinib in autoimmune ...
Taiwan News20d
Corvus Pharmaceuticals Announces Initiation of Phase 2 Clinical Trial of Soquelitinib for Patients with Autoimmune Lymphoproliferative Syndrome (ALPS)
ITK inhibition intended to address dysregulation of T cells that causes ALPS and has been shown to be effective at treating the disease in preclinical models BURLINGAME, Calif., March 12, 2025 (GLOBE ...
Nasdaq20d
Corvus Begins Phase 2 Trial For Soquelitinib In Rare Genetic Disease, ALPS
(RTTNews) - Corvus Pharmaceuticals (CRVS), Wednesday announced the initiation of a Phase 2 clinical trial for soquelitinib, an investigational drug, in partnership with the National Institute of ...
Investing20d
NIH and Corvus test drug for rare genetic disorder
BURLINGAME, Calif. - The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has launched a Phase 2 clinical trial in collaboration with ...
WOOD-TV20d
Corvus Pharmaceuticals Announces Initiation of Phase 2 Clinical Trial of Soquelitinib for Patients with Autoimmune Lymphoproliferative Syndrome (ALPS)
ITK inhibition intended to address dysregulation of T cells that causes ALPS and has been shown to be effective at treating the disease in preclinical models BURLINGAME, Calif., March 12, 2025 ...
Yahoo Finance21d
Corvus Pharmaceuticals Announces Initiation of Phase 2 Clinical Trial of Soquelitinib for Patients with Autoimmune Lymphoproliferative Syndrome (ALPS)
BURLINGAME, Calif., March 12, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the National Institute of ...